Multi‐platform comparison of plasma phosphorylated tau assays: analytical and workflow factors drive clinical implementation decisions
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-10 · 18 (4)
DOI: 10.1002/dad2.70465 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, online erschienen am 02.11.2026. Verfasst von Olga Sandoval-Boczkowska und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine University of British Columbia Vancouver Canada. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Roche Diagnostics, University of British Columbia.
Abstract (Originalsprache)
INTRODUCTION Multiple plasma phosphorylated tau assays are now commercially available for Alzheimer's disease (AD), yet clinical laboratories lack comprehensive comparative data to guide implementation. METHODS We assessed diagnostic accuracy and analytical performance in 273 participants with paired plasma and cerebrospinal fluid (CSF). CSF AD core biomarkers served as the reference standard. Index tests included three plasma tau phosphorylated at residue 217 (pTau217) assays (Roche, Fujirebio, Meso Scale Discovery [MSD]) and a pTau181 assay (Roche). RESULTS Participants: median age 70 [IQR: 64 to 76] years, 42% female, and 60% AD‐positive. pTau217 assays showed comparable accuracy (area under the curve [AUC] 0.88 to 0.89) exceeding pTau181 (AUC 0.85). All assays were resistant to hemolysis, icterus, and lipemia. Automated assays (Roche, Fujirebio) showed superior analytical precision and freeze/thaw stability (≥6 cycles) compared to the manual MSD assay (two cycles). DISCUSSION With comparable diagnostic accuracy across pTau217 platforms, analytical performance, and operational suitability became decisive implementation differentiators.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine University of British Columbia Vancouver Canada.
- Department of Psychiatry University of British Columbia Vancouver Canada.
- Division of Neurology Department of Medicine University of British Columbia Vancouver Canada.
- Department of Pathology and Laboratory Medicine St. Paul's Hospital Providence Health Care Vancouver Canada.
ORCID-Profile: Olga Sandoval-Boczkowska, John R Best, Rachael J Y Smith, Cyril Helbling, Ging-Yuek Robin Hsiung, Jacqueline A Pettersen, Haakon B Nygaard, Mari L DeMarco
Förderung
- Roche Diagnostics
- University of British Columbia
Zitieren
APA
Sandoval-Boczkowska, O., Best, J. R., Smith, R. J. Y., Burns, L., Helbling, C., Hsiung, G. R., Pettersen, J. A., Lee, P. E., Henri-Bhargava, A., Nygaard, H. B., & DeMarco, M. L. (2026). Multi‐platform comparison of plasma phosphorylated tau assays: analytical and workflow factors drive clinical implementation decisions. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 18(4). https://doi.org/10.1002/dad2.70465
Vancouver
Sandoval-Boczkowska O, Best JR, Smith RJY, Burns L, Helbling C, Hsiung GR, et al. Multi‐platform comparison of plasma phosphorylated tau assays: analytical and workflow factors drive clinical implementation decisions. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2026;18(4). doi:10.1002/dad2.70465
BibTeX
@article{SandovalBoczkowska2026,
author = {Sandoval-Boczkowska, Olga and Best, John R and Smith, Rachael J Y and Burns, Laura and Helbling, Cyril and Hsiung, Ging-Yuek Robin and Pettersen, Jacqueline A and Lee, Philip E and Henri-Bhargava, Alexandre and Nygaard, Haakon B and DeMarco, Mari L},
title = {Multi‐platform comparison of plasma phosphorylated tau assays: analytical and workflow factors drive clinical implementation decisions},
journal = {Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring},
year = {2026},
volume = {18},
number = {4},
doi = {10.1002/dad2.70465}
}
EUVIMED